NYSE - Delayed Quote USD

Enzo Biochem, Inc. (ENZ)

1.1300

-0.0200

(-1.74%)

At close: April 18 at 4:00 PM EDT

Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

Simply Wall St. last month

ENZ
-1.74%
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy mark

GlobeNewswire last month

ENZ
-1.74%
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company’s Board of Directors to hold office for a term ending a

GlobeNewswire 2 months ago

ENZ
-1.74%
Here’s Why Laughing Water Capital Sold Enzo Biochem Inc (ENZ)

Laughing Water Capital, an investment management company, released its fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, investment in the fund returned 3.2% bringing the yearly returns to 11.8%, net of all fees and expenses. The SP500TR and R2000 returned 11.7% and 14.0% during the quarter, respectively, […]

Insider Monkey 2 months ago

ENZ
-1.74%
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023. First Quarter Highlights The Company's Life Sciences division's first quarter revenue improved year-over-year by 10% driven by increased demand in multiple product areas, and stability in our multi-pronged channel to market approach. The Life Sciences division's first quarter gross margin was 44.3%, which impro

GlobeNewswire 4 months ago

ENZ
-1.74%
ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update. Fourth Quarter Highlights In July 2023, Enzo Biochem closed on the sale of assets used in the operation of Enzo Clinical Labs for a cash purchase price of $113,250,000, resulting in the full divestment of Enzo’s clinical laborat

GlobeNewswire 5 months ago

ENZ
-1.74%
Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. “In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division,” sai

GlobeNewswire 5 months ago

ENZ
-1.74%
Enzo Biochem (NYSE:ENZ) shareholders have endured a 63% loss from investing in the stock five years ago

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...

Simply Wall St. 6 months ago

ENZ
-1.74%
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. “We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.” Chairperson of the Board Mary Tagliaferri, MD stated, “Hamid successfully led the Co

GlobeNewswire 7 months ago

ENZ
-1.74%
Here’s Why Laughing Water Capital Made a Position in Enzo Biochem (ENZ)

Laughing Water Capital, an investment management company, released its second-quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, investment in the fund returned 13.8%, net of all fees and expenses, compared to the SP500TR and the R2000 returns of 8.7% and 5.2%, respectively. The fund’s return so far […]

Insider Monkey 8 months ago

ENZ
-1.74%
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023. ASSET SALE Enzo Biochem has completed the prev

GlobeNewswire 8 months ago

ENZ
-1.74%
LH
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results

- Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23 FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period. As previously reported, on March 16, 2023, Enzo Biochem announced tha

GlobeNewswire 9 months ago

ENZ
-1.74%
Enzo Biochem, Inc.'s (NYSE:ENZ) Popularity With Investors Is Under Threat From Overpricing

There wouldn't be many who think Enzo Biochem, Inc.'s ( NYSE:ENZ ) price-to-sales (or "P/S") ratio of 1.3x is worth a...

Simply Wall St. 10 months ago

ENZ
-1.74%
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock. Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the

GlobeNewswire 10 months ago

ENZ
-1.74%
$Enzo Biochem Insiders Added US$11m Of Stock To Their Holdings \$
Enzo Biochem Insiders Added US$11m Of Stock To Their Holdings \

Over the last year, a good number of insiders have significantly increased their holdings in Enzo Biochem, Inc...

Simply Wall St. 10 months ago

ENZ
-1.74%
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders

FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“La

GlobeNewswire 11 months ago

ENZ
-1.74%

Performance Overview

Return	ENZ	S&P 500
YTD	-18.71%	+5.06%
1-Year	-55.69%	+20.71%
3-Year	-66.07%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Enzo Biochem, Inc. (ENZ)

Enzo Biochem (NYSE:ENZ) shareholders have endured a 69% loss from investing in the stock three years ago

Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

Here’s Why Laughing Water Capital Sold Enzo Biochem Inc (ENZ)

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

Enzo Biochem (NYSE:ENZ) shareholders have endured a 63% loss from investing in the stock five years ago

Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

Here’s Why Laughing Water Capital Made a Position in Enzo Biochem (ENZ)

Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results

Enzo Biochem, Inc.'s (NYSE:ENZ) Popularity With Investors Is Under Threat From Overpricing

Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

Enzo Biochem Insiders Added US$11m Of Stock To Their Holdings \

Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders

Performance Overview